Multidisciplinary Cancer Investigation
Sun, Dec 22, 2024
[Archive]
Volume 5, Issue 3 (Multidisciplinary Cancer Investigation – July 2021)
Multidiscip Cancer Investig 2021, 5(3): 1-12 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Yan J, Li T, Wang Y, Zhu H, Liu R, Lei Z et al . The Efficacy and Safety of Iodine-125 Implantation Combined with Gemcitabine in the Treatment of Advanced Pan- creatic Cancer: A Systematic Review and Meta-analysis. Multidiscip Cancer Investig 2021; 5 (3) :1-12
URL: http://mcijournal.com/article-1-309-en.html
URL: http://mcijournal.com/article-1-309-en.html
1- Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China & Department of Postgraduate, Qinghai University, Xining, China , 583720460@qq.com
2- Department of Orthopedics, Sichuan People's Hospital, Chengdu, China & Department of Postgraduate, Chengdu Medical College, Chengdu, China
3- Department of Radiology, Chengdu Medical College, Chengdu, China
4- Department of Ultrasound Medicine, People’s Hospital of Tibet Autonomous Region, Lhasa, China & Department of Postgraduate, Tibet University, Lhasa, China
5- Nanchong Central Hospital, North Sichuan Medical College, Nanchong, China
6- Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China
2- Department of Orthopedics, Sichuan People's Hospital, Chengdu, China & Department of Postgraduate, Chengdu Medical College, Chengdu, China
3- Department of Radiology, Chengdu Medical College, Chengdu, China
4- Department of Ultrasound Medicine, People’s Hospital of Tibet Autonomous Region, Lhasa, China & Department of Postgraduate, Tibet University, Lhasa, China
5- Nanchong Central Hospital, North Sichuan Medical College, Nanchong, China
6- Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China
Abstract: (1858 Views)
Introduction: A systematic review and meta-analysis was conducted to assess the efficacy and safety of iodine-125 implantation combined with gemcitabine in the treatment of advanced pancreatic cancer.
Methods: PubMed, Chinese National Knowledge Infrastructure database (CNKI), Cochrane Library, Embase, and Wanfang database through Oct 2020 were searched
for randomized controlled trials (RCTs) and retrospective studies assessing the efficacy
and safety of iodine-125 implantation combined with gemcitabine in the treatment of advanced pancreatic cancer. The main outcome measures included the overall remission [complete response (CR)+partial response (PR)] rate, overall survival (OS), hypofunction of the liver, clinical benefit response (CBR) rate, survival rate, and adverse events.
Results: Totally, 19 studies involving 1496 patients were included in the current systematic review and meta-analysis. The pooled results showed that efficacy and safety of patients treated with Iodine-125 combined with gemcitabine were superior to those undergoing gemcitabine alone: overall remission (CR+PR) rate [odds ratio (OR)=3.10, 95% confidence interval (CI): 2.40, 4.00; P<0.00001], OS [hazard ratio (HR)=0.56, 95% CI: 0.47, 0.68; P<0.00001], hypofunction of liver (OR=1.08, 95% CI: 0.67, 1.74;
P=0.75), CBR rate (OR=3.85, 95% CI: 2.83, 5.22; P<0.00001), survival rate of six months (OR=3.44 95% CI: 1.83, 6.46) and survival rate of 12 months (OR=2.67, 95% CI: 1.68, 4.26). And there was no statistical association in adverse events between the groups.
Conclusions: The combination of iodine-125 seed implantation and gemcitabine significantly prolonged the survival of patients with pancreatic cancer, compared with the gemcitabine alone, indicating a better prognosis.
Methods: PubMed, Chinese National Knowledge Infrastructure database (CNKI), Cochrane Library, Embase, and Wanfang database through Oct 2020 were searched
for randomized controlled trials (RCTs) and retrospective studies assessing the efficacy
and safety of iodine-125 implantation combined with gemcitabine in the treatment of advanced pancreatic cancer. The main outcome measures included the overall remission [complete response (CR)+partial response (PR)] rate, overall survival (OS), hypofunction of the liver, clinical benefit response (CBR) rate, survival rate, and adverse events.
Results: Totally, 19 studies involving 1496 patients were included in the current systematic review and meta-analysis. The pooled results showed that efficacy and safety of patients treated with Iodine-125 combined with gemcitabine were superior to those undergoing gemcitabine alone: overall remission (CR+PR) rate [odds ratio (OR)=3.10, 95% confidence interval (CI): 2.40, 4.00; P<0.00001], OS [hazard ratio (HR)=0.56, 95% CI: 0.47, 0.68; P<0.00001], hypofunction of liver (OR=1.08, 95% CI: 0.67, 1.74;
P=0.75), CBR rate (OR=3.85, 95% CI: 2.83, 5.22; P<0.00001), survival rate of six months (OR=3.44 95% CI: 1.83, 6.46) and survival rate of 12 months (OR=2.67, 95% CI: 1.68, 4.26). And there was no statistical association in adverse events between the groups.
Conclusions: The combination of iodine-125 seed implantation and gemcitabine significantly prolonged the survival of patients with pancreatic cancer, compared with the gemcitabine alone, indicating a better prognosis.
Select article type: Review Article |
Subject:
Health Services, Quality of Life and Outcomes
Received: 2021/02/28 | Accepted: 2021/06/15 | ePublished: 2021/07/27
Received: 2021/02/28 | Accepted: 2021/06/15 | ePublished: 2021/07/27
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
